Clinical trials: Squamous Cell Carcinoma
Non Small Cell Lung Cancer
Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer
This study will test the activity of single-agent EC145 and the combination of EC145 plus docetaxel against the current standard docetaxel in second line Non Small Cell Lung Cancer (NSCLC) (adenocarcinoma, squamous, adenosquamous…
- Trial name
- TARGET (NCT01577654)
- Testing
- EC145, EC145 + Docetaxel, Docetaxel
- Volunteers
- 203 people
- Sponsor
- Endocyte
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC)
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer.
- Conditions
- Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
- Trial name
- NCT04844073
- Testing
- TAK-186
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 95 people
- Sponsor
- Takeda
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Head and Neck Cancer
Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00022217
- Testing
- carboplatin, cisplatin-e therapeutic implant, paclitaxel
- Where
- 4 sites in United States
- Sponsor
- Matrix Pharmaceutical
Squamous Cell Carcinoma, Alpha Radiation
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients
This is a multi-center clinical study enrolling up to 28 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral…
- Conditions
- Squamous Cell Carcinoma, Alpha Radiation, Immunocompromised, Carcinoma, Squamous
- Trial name
- DaRT (NCT06615635)
- Testing
- DaRT seeds
- Where
- 11 sites in United States, Israel
- Volunteers
- 28 people
- Sponsor
- Alpha Tau Medical LTD.
Squamous Cell Carcinoma
Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device.
- Trial name
- DaRT (NCT03015883)
- Testing
- Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 28 people
- Sponsor
- Alpha Tau Medical LTD.
Gynecologic Cancer, Colorectal Cancer
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects…
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05292859
- Testing
- Neoantigen specific TCR-T cell drug product
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device (DaRT) as a treatment prior to additional radiation or chemo therapy.
- Trial name
- NCT05065346
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT
- Where
- Israel
- Volunteers
- 79 people
- Sponsor
- Alpha Tau Medical LTD.
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
This study was conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03525392
- Testing
- 177Lu-3BP-227 (also called 177Lu-IPN01087)
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 14 people
- Sponsor
- Ipsen
Head and Neck Squamous Cell Carcinoma
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in participants with head and neck squamous cell…
- Trial name
- ELEVATE HNSCC (NCT04854499)
- Testing
- Magrolimab, Pembrolizumab, Docetaxel
- Where
- 88 sites in United States, Australia and 9 more
- Volunteers
- 193 people
- Sponsor
- Gilead Sciences
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV).
- Trial name
- NCT06319963
- Testing
- Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Theravectys S.A.
Non-Small Cell Lung Cancer, Breast Cancer
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
This is a Phase 1b/2, multi-center study to assess the safety and efficacy of ibrutinib in combination with durvalumab (MEDI4736) in participants with relapsed or refractory solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- NCT02403271
- Testing
- Ibrutinib, Durvalumab
- Where
- 17 sites in United States
- Volunteers
- 124 people
- Sponsor
- Pharmacyclics LLC.
Head and Neck Cancer
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or…
- Trial name
- NCT03769506
- Testing
- ASP-1929 Photoimmunotherapy, Physician's Choice SOC
- Where
- 22 sites in United States, India and 2 more
- Volunteers
- 135 people
- Sponsor
- Rakuten Medical, Inc.
Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations
The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with advanced/metastatic lung cancer and fibroblast growth factor (FGF), vascular endothelial growth factor receptor…
- Conditions
- Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, NSCLC, Small Cell Lung Cancer
- Trial name
- NCT02109016
- Testing
- Lucitanib
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 18 people
- Sponsor
- Clovis Oncology, Inc.
Locally Advanced Head and Neck Squamous Cell Carcinoma
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed…
- Trial name
- eVOLVE-HNSCC (NCT06129864)
- Testing
- volrustomig
- Where
- 306 sites in United States, Austria and 21 more
- Volunteers
- 1,145 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APT-CUBE (NCT05473156)
- Testing
- AP203
- Where
- Taiwan
- Volunteers
- 168 people
- Sponsor
- AP Biosciences Inc.
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic, and potential clinical benefit of PF-07209960…
- Conditions
- Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04628780
- Testing
- PF-07209960
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Cancer
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
We intend to establish an efficient method for plasma cfDNA extraction and Bisulfite transformation to facilitate the detection of DNA methylation status using multiplex fluorescence PCR.
- Trial name
- NCT05685524
- Testing
- DNA methylation test
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd
Breast Cancer, Ovarian Cancer
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05239143
- Testing
- P-MUC1C-ALLO1 CAR-T cells, Rimiducid
- Where
- 14 sites in United States
- Volunteers
- 180 people
- Sponsor
- Poseida Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.